Evoked potential abnormalities in RRMS patients are improved under natalizumab therapy

Thus far, the direct impact of natalizumab (Tysabri ®) on functional parameters of nerve conduction assessed by evoked potentials (visual (VEP), somatosensory (SEP) and motor evoked potentials (MEP)) has not been investigated. VEP, MEP and SEP data were measured in a cohort of 44 relapsing-remitting multiple sclerosis (RRMS) patients and analyzed 12 months prior to initiation of natalizumab treatment, at the timepoint of treatment initiation and one year later. Sum scores (VEP, MEP, SEP) were evaluated and correlated with the expanded disability status scale (EDSS) and EDSS functional scores. Improvement of the…